[Surg Endosc (2006) 20: 64–70, DOI: 10.1007/s00464-005-0104-y]
On page 65, in column 1 of the “Patients and methods” section, the wrong study number was published. The first sentence under the heading “Study design and treatments” should read:
This was a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (Study 14CL308) designed to evaluate the efficacy and safety of 6 and 12 mg alvimopan for the management of POI in patients undergoing BR or TAH.
Author information
Authors and Affiliations
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s00464-005-0104-y
Rights and permissions
About this article
Cite this article
Viscusi, E., Goldstein, S., Witkowski, T. et al. Alvimopan, a perpherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery. Surg Endosc 20, 537 (2006). https://doi.org/10.1007/s00464-006-3025-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-006-3025-5